PDCD1 and neoplasm: This implies that either decreasing STAT1 activity by JAKi to block expression of immunosuppressive molecules (including PARP14) or boosting STAT1 by PARP14i to enhance tumour immunogenicity are both viable approaches to increasing response to α-PD-1 therapy.